title: Increased myocardial vulnerability to ischemia-reperfusion injury in the presence of left ventricular hypertrophy.
abstract: OBJECTIVE
  Despite its high prevalence among patients suffering myocardial infarction, the significance of left ventricle hypertrophy for infarct size is not known. We asked whether infarct size might be increased by this condition, and whether any such increase might be associated with an increased mitochondrial damage following coronary occlusion.
  
  
  METHODS
  Occlusion of the left descending artery in isolated, perfused hearts of SHR-SP (spontaneously hypertensive rat stroke-prone) (left ventricular hypertrophy) or Wistar-Kyoto (WKY) (control) rats was used, followed by reperfusion with or without exendin-4 (Exe-4), a glucagon-like peptide-1 receptor agonist. Infarct size relative to area-at-risk was determined. Separately, mitochondria were isolated after global ischemia. Activities of complexes III and IV and amounts of selected complex subunits and cytochromes a, b, c, and c1 were determined.
  
  
  RESULTS
  Infarct size (ischemia 35  min and 120  min reperfusion) was 65.8% (±3.3%) and 37.1% (±3.4%) in the SHR-SP and WKY hearts, respectively (P < 0.05). Exe-4 significantly decreased infarct size and hypercontracture in WKY, but not in SHR-SP, hearts. After ischemia 15  min in SHR-SP hearts, Exe-4 reduced the infarct (26.6%, ±3.8% to 9.3% ± 1.5%; P < 0.05). Mitochondria from postischemic SHR-SP hearts showed a reduction of complex III (368.1 ± 37.5 to 175.8 ± 23.0  nmoles/min × mg; P < 0.05) and complex IV (14.4 ± 0.22 to 5.8 ± 0.8 1/s × mg; P < 0.05) activities and decreased amounts of cytochromes a, b, and c.
  
  
  CONCLUSIONS
  Hearts from hypertensive (SHR-SP) rats with left ventricle hypertrophy appeared more vulnerable to ischemia-reperfusion injury, as supported by a more profound infarct development and an earlier loss of postconditioning by Exe-4. Mitochondrial complexes III and IV were identified among possible loci of this increased, hypertrophy-associated vulnerability.
authors.affiliation: aDepartment of Medical Sciences and The Danish National Research Foundation Centre for Heart Arrhythmia, University of CopenhagenbCardiac Catheterization Laboratory, The Heart Centre, Rigshospitalet, Copenhagen, Denmark*Søren Mølgaard and Barbara Faricelli contributed equally to the writing of this article.
authors.forename: Søren
authors.initials: S
authors.lastname: Mølgaard
authors.forename: Barbara
authors.initials: B
authors.lastname: Faricelli
authors.forename: Max
authors.initials: M
authors.lastname: Salomonsson
authors.forename: Thomas
authors.initials: T
authors.lastname: Engstrøm
authors.forename: Marek
authors.initials: M
authors.lastname: Treiman
mesh_terms: D000818:Animals; D003580:Cytochromes / Q000187:drug effects / Q000378:metabolism; D014450:Electron Transport Complex III / Q000187:drug effects / Q000378:metabolism; D003576:Electron Transport Complex IV / Q000187:drug effects / Q000378:metabolism; D000077270:Exenatide; D006321:Heart / Q000187:drug effects; D006973:Hypertension / Q000150:complications*; D017379:Hypertrophy, Left Ventricular / Q000150:complications*; D054795:Incretins / Q000494:pharmacology; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D015428:Myocardial Reperfusion Injury / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D010455:Peptides / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D012720:Severity of Illness Index; D014688:Venoms / Q000494:pharmacology
chemical_list: D003580:Cytochromes; D054795:Incretins; D010455:Peptides; D014688:Venoms; D000077270:Exenatide; D003576:Electron Transport Complex IV; D014450:Electron Transport Complex III